Rethinking child treatments

Developing evidence-based treatments - specifically for children

Releases

Releases

16. May, 2022

Cessatech reports last patient dosed in pharmacokinetic trial in children of lead candidate

Clinical trial 0206 will investigate the pharmacokinetics of CT001 in children aged 1-17 undergoing...

Read more

Releases

19. April, 2022

First quarter report Q1-2022

Cessatech A/S today releases its results for the period 1 January – 31 March...

Read more

Releases

8. March, 2022

Successful outcome from trial 0204

Cessatech reports successful outcome of bioavailability trial 0204 Topline results of clinical trial 0204...

Read more

Releases

3. March, 2022

Annual report 2021 published

Cessatech A/S publishes its annual report for the fiscal year 2021. “We managed to...

Read more

Releases

6. January, 2022

Changes to the Board of Directors – welcome to Rachel

Cessatech has appointed Rachel Curtis Gravesen as Observer to the Board of Directors with...

Read more

Facts about Children

Facts

15. March, 2022

Off-label use of medication in children continue to be the rule rather than the exception…

A systematic review of 31 studies with off-label prescription rates confirms the continued off-label...

Read more

Facts

3. March, 2022

Physical restraint of children in 79% of Scandinavian emergency departments

Physical restraint of children during painful procedures is used in 79% of Scandinavian emergency...

Read more

Facts

2. February, 2021

Ny forskning: Barn bör få smärtlindring vid vaccinationer och injektioner

Barn mår bra av smärtlindring vid vanliga vaccinationer och injektioner. Det säger den senaste...

Read more

Facts

8. September, 2020

Behov for større sikkerhed omkring medicin til børn og unge i Danmark

Kun 30% af markedsførte lægemidler i EU er godkendt til børn, og kun 50%...

Read more

Facts

31. August, 2020

DR.dk focus – Børn og ældre får medicin, der ikke er godkendt til dem

Kan give voldsomme bivirkninger, når børn og ældre får medicin, der ikke er godkendt til dem...

Read more

Experience

Proven track-record within drug development and product launches, in Europe, US and Asia.

The executive management team and the Board of Directors have a proven track-record within drug development, paediatric analgesic research, product launches and capital raising across all major markets.

Team
Lead Asset

CT001 – Nasal spray

Cessatech’s first product and lead asset, CT001, is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures. Today’s analgesic solutions often require an intravenous access which is not always feasible or easy and can be painful experience.

See details

Stay up to date!

Subscribe and get notified on Cessatech's latest news.